Drawing for ATHEROGENICS

USPTO serial 74602771

ATHEROGENICS

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
CHARLON, BARNEY
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ATHEROGENICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Miles J. Alexander

MILES J ALEXANDER KILPATRICK & CODY1100 PEACHTREE STSTE 2800ATLANTA, GA 30309-4530

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations for treatment of heart disordersABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 20, 1996ABN1ABANDONMENT - EXPRESS MAILED—
Sep 9, 1996CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 20, 1996CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 12, 1995CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 6, 1995DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance